Mutations of the CYP2C9 gene and the response to warfarin [2]

Surgery

Volumn 129, Issue 3, 2001, Pages 384-

  Yasar, U ^a   Oscarson, M ^a   Eliasson, E ^a   Sjoqvist F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN DERIVATIVE; CYTOCHROME P450 2C9; WARFARIN;

ANTICOAGULATION; DNA POLYMORPHISM; DRUG METABOLISM; GENE MUTATION; HETEROZYGOSITY; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 0035102197     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2001.113379     Document Type: Letter

References (6)

1. Human P450 metabolism of warfarin
2. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
3. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
4. CYP2A6: A human coumarin 7-hydroxylase
5. Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro
6. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions